TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06955169: Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Sponsor: RTOG Foundation, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 130 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,992,000

Rescue Site Savings

+$1,328,000

Unlock Full NCT06955169 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06955169 Rescue Dossier →